CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: CEL-SCI is a biotechnology company focused on the development of Multikine (for cancer treatment) and L.E.A.P.S. technology. The company has not generated revenue from product sales and relies on capital raises, licensing agreements, and loans to fund research and development (R&D) and clinical trials. The company is preparing for a Phase III clinical trial for Multikine.
Key Financial Metrics
| Metric | Nine Months Ended June 30, 2010 |
Nine Months Ended June 30, 2009 |
Three Months Ended June 30, 2010 |
Three Months Ended June 30, 2009 |
|---|---|---|---|---|
| Total Revenue | $91,500 | $50,093 | $30,900 | $30,450 |
| Net Income (Loss) | $17,813,874 | $(10,529,857) | $(601,124) | $(6,239,064) |
| Net Income (Loss) to Common Shareholders | $16,381,418 | $(10,996,524) | $(601,124) | $(6,705,731) |
| EPS (Basic) | $0.08 | $(0.09) | $(0.00) | $(0.05) |
| EPS (Diluted) | $(0.02) | $(0.09) | $(0.01) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $30,475,636 | $5,571,411 | $30,475,636 | $5,571,411 |
| Net Cash Used in Operating Activities | $(9,064,665) | $(3,044,463) | N/A | N/A |
| Net Cash Provided by Financing Activities | $6,308,874 | $6,985,892 | N/A | N/A |
| Total Assets | $42,107,624 | $46,027,598 | $42,107,624 | $46,027,598 |
| Total Liabilities | $7,425,817 | $37,186,954 | $7,425,817 | $37,186,954 |
| Derivative Liabilities | $5,175,372 | $35,113,970 | $5,175,372 | $35,113,970 |
Material Changes vs. Prior Period
- Net Income Turnaround: The company reported a net income of $17.8 million for the nine months ended June 30, 2010, compared to a net loss of $10.5 million in the same period in 2009. This reversal is primarily driven by a non-cash gain of $30.6 million on derivative instruments, resulting from a decline in the company's stock price which reduced the fair value of warrant liabilities.
- Derivative Liabilities: Total derivative liabilities decreased significantly from $35.1 million to $5.2 million due to the revaluation of warrants and the exercise of Series K and Series A warrants, which were reclassified from liabilities to equity.
- Operating Expenses: Research and development (R&D) expenses increased by approximately $3.9 million year-over-year (to $7.7 million) due to preparations for the Phase III clinical trial for Multikine. General and administrative expenses increased by $0.9 million year-over-year.
- Cash Position: Cash and cash equivalents decreased by $3.1 million during the nine-month period, despite the net income, due to significant cash burn from operations ($9.1 million) partially offset by financing proceeds ($6.3 million) from the exercise of warrants and options.
Guidance, Outlook, and Risks
- Clinical Trial Status: The company is preparing for the Phase III clinical trial for Multikine in the U.S., Canada, and other countries. The net cost to the company for this trial is estimated at $25 million, with two partners agreeing to fund a portion.
- Liquidity: Management believes it has sufficient capital to support operations for more than the next twelve months. The company maintains a $5 million Equity Line of Credit (no drawdowns in the period) and has a related-party loan of approximately $1.1 million from the President.
- Risks:
- Regulatory Approval: The ability to generate revenue is contingent upon completing clinical trials and obtaining FDA approval, which is uncertain.
- Capital Requirements: The company will need to raise additional capital or secure long-term financing to continue R&D and complete the Phase III trial.
- Derivative Volatility: Net income is heavily influenced by the fair value adjustments of derivative instruments (warrants), which fluctuate with the company's stock price and do not represent cash flow.
- Subsequent Event: On August 3, 2010, the Board approved an amendment to Series M warrants, reducing the exercise price to $0.60 and the number of shares purchasable from 8.8 million to 6 million.
Investor Verification Checklist
- Non-Cash Gains: Verify the impact of the $30.6 million gain on derivative instruments on the reported net income; this is a non-cash accounting adjustment.
- Cash Burn Rate: Confirm the sustainability of the $9.1 million cash used in operating activities against the $30.5 million cash balance.
- Phase III Funding: Assess the progress of securing the remaining funding for the estimated $25 million Phase III clinical trial.
- Warrant Liability: Monitor the remaining $5.2 million in derivative liabilities and the potential for future volatility in earnings based on stock price movements.
- Related Party Loan: Review the terms of the $1.1 million loan from the President, including the 15% interest rate and conversion options.